Key facts
- It has raised $1.3M; the latest was Seed Round ($1.3M) in Nov 2025.
- Notable investors include Venrex Investment Management, Tonic Ventures, Apex Capital (Portugal), Palette Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Graymatter Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Graymatter Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Graymatter Labs
Provider of a plant-based, drinkable nootropic and adaptogen supplement intended to offer a natural alternative to prescription stimulants and caffeine. The company's supplement features a curated blend of nootropics, adaptogens, and plant-based energy compounds, enabling individuals seeking focused, calm, and sustained cognitive energy without the side effects of traditional stimulants, and offering a scientifically designed everyday mental performance support.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Chicago, IL, United States
- Founded
- 2021
- Employees
- 10
- Website
- trygraymatter.com/
- Ownership
- Privately Held (backing)
Graymatter Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Graymatter Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Graymatter Labs in its N-PORT filings yet. We sweep new filings monthly.